Topadur Pharma
DEBRA Research joins with Topadur to advance therapies for dystrophic epidermolysis bullosa
People with the rare and debilitating genetic skin disorder have extremely fragile skin that is prone to blistering and wounds
LEO Pharma to acquire Replay gene therapy platform
The acquisition will advance innovation for patients with rare skin diseases
DEBRA Research and University Medical Center Groningen launch clinical trial site for epidermolysis bullosa
This rare genetic disorder causes skin to become extremely fragile
DEBRA and Queen Mary partner to advance epidermolysis bullosa drug development
Around 500,000 people worldwide are affected by the group of rare genetic skin conditions
Dermaliq and DEBRA partner to advance epidermolysis bullosa drug delivery
Approximately 500,000 people worldwide are affected by the rare genetic skin disorders
LEO and DEBRA Research partner to advance epidermolysis bullosa treatments
There is currently no cure for the group of rare inherited skin disorders
Almirall gains rights to Eloxx’s rare dermatological disease asset in deal worth over $470m
ZKN-013 is designed to overcome nonsense mutations in rare skin diseases such as junctional epidermolysis bullosa